[Malignant diffuse peritoneal mesothelioma: clinical and therapeutic aspects. Apropos of a case with gelatinous ascites].
Peritoneal mesothelioma ranks second in frequency after pleural mesothelioma. A well-established clinical entity since 1960, mesothelioma is increasingly frequent due to improvements in diagnostic methods and to the fairly wide industrial use of asbestos, a well-known carcinogenic substance for mesothelial cells. The diagnosis of malignant peritoneal mesothelioma rests on a corpus of convergent data. Treatment consists of surgery combined with radiotherapy and chemotherapy. The mean survival from the time of diagnosis is 8-10 months.
J E
JE
Kunnert
D
D
Christmann
J
J
Marescaux
M
M
Weill-Bousson
J L
JL
Pasquali
D
D
Storck
D001201:Ascites / Q000209:etiology; D004781:Environmental Exposure; D006801:Humans; D008297:Male; D008654:Mesothelioma / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy; D008875:Middle Aged; D010534:Peritoneal Neoplasms / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000628:therapy
Mésothéliome péritonéal malin diffus: aspects cliniques et thérapeutiques. A propos de 1 cas accompagné d'ascite gélatineuse.